The BioCentury Show
Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.
Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.
The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine.
Don't miss this event, every two weeks, now available as a video webcast or audio podcast.
Podcasting since 2024 • 50 episodes
The BioCentury Show
Latest Episodes
Ep. 98 - Inside Precision Oncology’s Next Chapter with Fore’s Bill Hinshaw
When Bill Hinshaw looks back across the arc of his career — from his early days helping to commercialize Gleevec to his present role leading Fore Biotherapeutics — he sees a precision oncology field transformed by technological ambition, yet st...
•
Season 4
•
Episode 98
•
37:38
Popular Episode - Reimagining FDA: Steve Usdin on Designing the Drug Regulator of the Future
This is a previously recorded episode of The BioCentury Show from September 5, 2025. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all pr...
•
Season 4
•
38:39
Ep. 97 – From NIH to Industry: Zerhouni Warns Policy & Rhetoric Threaten U.S. Science
Elias Zerhouni personifies the American dream. He arrived in the U.S. from Algeria as a young man with a couple of hundred dollars in his pocket. Talent, ambition and hard work propelled him into a successful academic career. In 2002, he was no...
•
Season 4
•
Episode 97
•
34:11
Ep. 96 – From Pharma Partnering to Biotech CEO: Sophie Kornowski on Boston Pharma’s Playbook
It took Sophie Kornowski under four years as CEO of Boston Pharma to bring it from a pipeline full of in-licensed assets to an acquisition by GSK for about $2 billion in total deal value for a single MASH program. Though her first gig as a biot...
•
Season 4
•
Episode 96
•
32:17
Ep. 95 - Kymera CEO Nello Mainolfi: Matching Degrader Chemistry to the Problem
Kymera Therapeutics has a clear mission: to transform immunology with targeted protein degraders that enable “oral drugs with biologics-like activity,” CEO Nello Mainolfi told The BioCentury Show. A pioneer in one of biopharma’s most closely wa...
•
Season 4
•
Episode 95
•
31:33
.jpg)
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
